Due to fewer side effects in regard to grade 3 or 4 neutropenia, thrombocytopenia, febrile neutropenia, diarrhea and due to recommended G‐CSF usage with (m)FOLFIRINOX protocol, Gem‐Nab is currently used as first‐line therapy regimen in the majority of cases in most European countries.10 The gene discussed is CSF3; the disease is Decreased total neutrophil count.